-
1
-
-
33644910397
-
Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: The European perspective
-
Chatal JF. Radioimmunotherapy, a new breakthrough in the treatment of follicular non-Hodgkin's lymphoma: the European perspective. Cancer Biother Radiopharm. 2006; 21:1-4.
-
(2006)
Cancer Biother Radiopharm
, vol.21
, pp. 1-4
-
-
Chatal, J.F.1
-
2
-
-
0036840133
-
Radioimmunotherapy of B-cell non-hodgkin's lymphoma: From clinical trials to clinical practice
-
Juweid M. Radioimmunotherapy of B-cell non-hodgkin's lymphoma: from clinical trials to clinical practice. J Nucl Med. 2002;43:1507-1529.
-
(2002)
J Nucl Med
, vol.43
, pp. 1507-1529
-
-
Juweid, M.1
-
3
-
-
0036255688
-
Targeted therapy of cancer with radiolabeled antibodies
-
Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;5:693-713.
-
(2002)
J Nucl Med
, vol.5
, pp. 693-713
-
-
Goldenberg, D.M.1
-
4
-
-
33846549106
-
Advances in cancer therapy with radiolabeled monoclonal antibodies
-
Goldenberg DM, Sharkey RM. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging. 2006;50:248-264.
-
(2006)
Q J Nucl Med Mol Imaging
, vol.50
, pp. 248-264
-
-
Goldenberg, D.M.1
Sharkey, R.M.2
-
5
-
-
33644869654
-
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
-
Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol. 2006; 24:823-834.
-
(2006)
J Clin Oncol
, vol.24
, pp. 823-834
-
-
Goldenberg, D.M.1
Sharkey, R.M.2
Paganelli, G.3
Barbet, J.4
Chatal, J.F.5
-
6
-
-
0033039587
-
Pretargeting with the affinity enhancement system for radioimmunotherapy
-
Barbet J, Kraeber-Bodere F, Vuillez JP, Gautherot E, Rouvier E, Chatal JF. Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother Radiopharm. 1999;14:153-166.
-
(1999)
Cancer Biother Radiopharm
, vol.14
, pp. 153-166
-
-
Barbet, J.1
Kraeber-Bodere, F.2
Vuillez, J.P.3
Gautherot, E.4
Rouvier, E.5
Chatal, J.F.6
-
7
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
8
-
-
0028929803
-
Angiogenesis in cancer, vascular, rheumatoid and other disease
-
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
-
(1995)
Nat Med
, vol.1
, pp. 27-31
-
-
Folkman, J.1
-
9
-
-
0026083903
-
Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma
-
Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
-
(1991)
N Engl J Med
, vol.324
, pp. 1-8
-
-
Weidner, N.1
Semple, J.P.2
Welch, W.R.3
Folkman, J.4
-
10
-
-
0027717345
-
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
-
Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
-
(1993)
Am J Pathol
, vol.143
, pp. 401-409
-
-
Weidner, N.1
Carroll, P.R.2
Flax, J.3
Blumenfeld, W.4
Folkman, J.5
-
11
-
-
0029830557
-
Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer
-
Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst. 1996;88:1764-1769.
-
(1996)
J Natl Cancer Inst
, vol.88
, pp. 1764-1769
-
-
Heimann, R.1
Ferguson, D.2
Powers, C.3
Recant, W.M.4
Weichselbaum, R.R.5
Hellman, S.6
-
12
-
-
0038626211
-
Tumor response to radiotherapy regulated by endothelial cell apoptosis
-
Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155-1159.
-
(2003)
Science
, vol.300
, pp. 1155-1159
-
-
Garcia-Barros, M.1
Paris, F.2
Cordon-Cardo, C.3
-
13
-
-
0017183433
-
Association of medullary carcinoma of the thyroid with carcinoembryonic antigen
-
Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer. 1976;34:111-115.
-
(1976)
Br J Cancer
, vol.34
, pp. 111-115
-
-
Ishikawa, N.1
Hamada, S.2
-
14
-
-
0032898058
-
Comparative toxicity and efficacy of 1- and 2-step (bipecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer
-
Kraeber-Bodere F, Faivre-Chauvet A, Sai-Maurel C, et al. Comparative toxicity and efficacy of 1- and 2-step (bipecific antibody and bivalent hapten) radioimmunotherapy in CEA-producing medullary thyroid cancer. J Nucl Med. 1999;40:198-204.
-
(1999)
J Nucl Med
, vol.40
, pp. 198-204
-
-
Kraeber-Bodere, F.1
Faivre-Chauvet, A.2
Sai-Maurel, C.3
-
15
-
-
0032697614
-
Toxicity and efficacy of radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft: Comparison of iodine-131-labeled F(ab)2 and pretargeted bivalent hapten, and evaluation of repeated injections
-
Kraeber-Bodere F, Faivre-Chauvet, A, Sai-Maurel, C, et al. Toxicity and efficacy of radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft: comparison of iodine-131-labeled F(ab")2 and pretargeted bivalent hapten, and evaluation of repeated injections. Clin Cancer Res. 1999;5:3183s-3189s.
-
(1999)
Clin Cancer Res
, vol.5
-
-
Kraeber-Bodere, F.1
Faivre-Chauvet, A.2
Sai-Maurel, C.3
-
16
-
-
0032719527
-
Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial
-
Kraeber-Bodere F, Bardet S, Hoefnagel CA, et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine-131-labeled bivalent hapten: Preliminary results of a phase I/II clinical trial. Clin Cancer Res. 1999;5:3190s-3198s.
-
(1999)
Clin Cancer Res
, vol.5
-
-
Kraeber-Bodere, F.1
Bardet, S.2
Hoefnagel, C.A.3
-
17
-
-
33645834287
-
Survival improvement in medullary thyroid carcinoma patients given pretargeted CEA radioimmunotherapy
-
Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in medullary thyroid carcinoma patients given pretargeted CEA radioimmunotherapy. J Clin Oncol. 2006; 24:1705-1711.
-
(2006)
J Clin Oncol
, vol.24
, pp. 1705-1711
-
-
Chatal, J.F.1
Campion, L.2
Kraeber-Bodere, F.3
-
18
-
-
0036463694
-
Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft
-
Kraeber-Bodere F, Sai-Maurel C, Campion L, et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther. 2002;14:267-274.
-
(2002)
Mol Cancer Ther
, vol.14
, pp. 267-274
-
-
Kraeber-Bodere, F.1
Sai-Maurel, C.2
Campion, L.3
-
19
-
-
33644846851
-
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors
-
Kulke M, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-406.
-
(2006)
J Clin Oncol
, vol.24
, pp. 401-406
-
-
Kulke, M.1
Stuart, K.2
Enzinger, P.C.3
-
20
-
-
0017874586
-
-
Farker PJ, Speck JC. Protein and cell membrane iodination with a springly soluble chloramine; 1,3,4,6 tetrachloro-3a, 6a-diphenyl glycoluryl. Biophys Res Commun. 1978;80: 849-854.
-
Farker PJ, Speck JC. Protein and cell membrane iodination with a springly soluble chloramine; 1,3,4,6 tetrachloro-3a, 6a-diphenyl glycoluryl. Biophys Res Commun. 1978;80: 849-854.
-
-
-
-
21
-
-
22044444554
-
Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
-
Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood. 2005;106:125-134.
-
(2005)
Blood
, vol.106
, pp. 125-134
-
-
Yabu, T.1
Tomimoto, H.2
Taguchi, Y.3
Yamaoka, S.4
Igarashi, Y.5
Okazaki, T.6
-
22
-
-
0031906775
-
Expression of vascular endothelial growth factor in digestive neuroendocrine tumours
-
Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32:133-138.
-
(1998)
Histopathology
, vol.32
, pp. 133-138
-
-
Terris, B.1
Scoazec, J.Y.2
Rubbia, L.3
-
23
-
-
28044447317
-
A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETS) [abstract]
-
Abstract 4008
-
Kulke M, Lenz H, Meropol N, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETS) [abstract]. J Clin Oncol. 2005;23(suppl). Abstract 4008.
-
(2005)
J Clin Oncol
, vol.23
, Issue.SUPPL.
-
-
Kulke, M.1
Lenz, H.2
Meropol, N.3
-
24
-
-
28044441251
-
Improved progression free survival (PFS) and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract]
-
Abstract 4007
-
Yao J, Ng C, Hoff P, et al. Improved progression free survival (PFS) and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab [abstract]. J Clin Oncol. 2005;23(suppl). Abstract 4007.
-
(2005)
J Clin Oncol
, vol.23
, Issue.SUPPL.
-
-
Yao, J.1
Ng, C.2
Hoff, P.3
-
25
-
-
23544478499
-
A phase II study of thalidomide in metastatic neuroendocrine tumors [abstract]
-
Abstract 1931
-
Xu Y, Ellison C, Martin E, et al. A phase II study of thalidomide in metastatic neuroendocrine tumors [abstract]. Proc Am Soc Clin Oncol. 2002;20(suppl). Abstract 1931.
-
(2002)
Proc Am Soc Clin Oncol
, vol.20
, Issue.SUPPL.
-
-
Xu, Y.1
Ellison, C.2
Martin, E.3
-
26
-
-
0029892557
-
Microvessel count: An indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma
-
Fontanini G, Vignati S, Pacini F, Pollina L, Basolo F. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Mod Pathol. 1996;9:636-641.
-
(1996)
Mod Pathol
, vol.9
, pp. 636-641
-
-
Fontanini, G.1
Vignati, S.2
Pacini, F.3
Pollina, L.4
Basolo, F.5
-
27
-
-
33846850223
-
Vandetanib (ZD6474): An orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis
-
Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs. 2007;16:239-249.
-
(2007)
Expert Opin Investig Drugs
, vol.16
, pp. 239-249
-
-
Herbst, R.S.1
Heymach, J.V.2
O'Reilly, M.S.3
Onn, A.4
Ryan, A.J.5
-
28
-
-
0036327411
-
Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts
-
Kinuya S, Kawashima A, Yokoyama K, et al. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med. 2002;43:1084-1089.
-
(2002)
J Nucl Med
, vol.43
, pp. 1084-1089
-
-
Kinuya, S.1
Kawashima, A.2
Yokoyama, K.3
-
29
-
-
1842847331
-
Benefits of combined radioimmunotherapy and antiangiogenic therapy in a liver metastasis model of human colon cancer cells
-
Li XF, Kinuya S, Yokoyama K, et al. Benefits of combined radioimmunotherapy and antiangiogenic therapy in a liver metastasis model of human colon cancer cells. Eur J Nucl Med Mol Imaging. 2002;12:1669-1674.
-
(2002)
Eur J Nucl Med Mol Imaging
, vol.12
, pp. 1669-1674
-
-
Li, X.F.1
Kinuya, S.2
Yokoyama, K.3
-
30
-
-
3142712910
-
Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy
-
Kinuya S, Yokoyama K, Koshida K, et al. Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy. Eur J Nucl Med Mol Imaging. 2004;31:981-985.
-
(2004)
Eur J Nucl Med Mol Imaging
, vol.31
, pp. 981-985
-
-
Kinuya, S.1
Yokoyama, K.2
Koshida, K.3
-
31
-
-
0036682030
-
Cilengitide targeting of alpha (v) beta integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts
-
Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cilengitide targeting of alpha (v) beta integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
-
(2002)
Cancer Res
, vol.62
, pp. 4263-4272
-
-
Burke, P.A.1
DeNardo, S.J.2
Miers, L.A.3
Lamborn, K.R.4
Matzku, S.5
DeNardo, G.L.6
-
32
-
-
0031440905
-
Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma
-
DeNardo SJ, Kroger LA, Lamborn KR, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer. 1997;80:2583-2590.
-
(1997)
Cancer
, vol.80
, pp. 2583-2590
-
-
DeNardo, S.J.1
Kroger, L.A.2
Lamborn, K.R.3
-
33
-
-
76249095295
-
Toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in mouse model of medullary thyroid carcinoma [abstract]
-
145P
-
Kraeber-Bodere F, Sai-Maurel C, Faivre-Chauvet A, et al. Toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in mouse model of medullary thyroid carcinoma [abstract]. J Nucl Med. 2005;46:145P.
-
(2005)
J Nucl Med
, vol.46
-
-
Kraeber-Bodere, F.1
Sai-Maurel, C.2
Faivre-Chauvet, A.3
-
34
-
-
19944422751
-
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases
-
Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004;6:553-563.
-
(2004)
Cancer Cell
, vol.6
, pp. 553-563
-
-
Winkler, F.1
Kozin, S.V.2
Tong, R.T.3
-
35
-
-
0038176480
-
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction
-
Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003;9:1957-1971.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 1957-1971
-
-
Wachsberger, P.1
Burd, R.2
Dicker, A.P.3
|